Find an expert

After completing his BSc and MSc (Hons) at the University of Canterbury (NZ), Dylan worked for five years as a Research Scientist at Antisoma Research Limited (London, UK), developing antibody-enzyme fusion proteins for cancer therapy. He returned to New Zealand to carry out his PhD research into antidepressant pharmacogenomics at the University of Otago. Afterwards, he continued working at the University of Otago as a Research Fellow, studying the biological function of genes involved with inflammatory bowel disease. Dylan moved to the United States in 2009 to perform postdoctoral training, researching the functional genetics of the VEGF-pathway and its relationship with cancer at the University of Chicago and, subsequently, the University of North Carolina, Chapel Hill.

In 2013, Dylan began working at QIMR Berghofer and has undertaken the functional follow-up of large-scale genetic studies of breast, endometrial and ovarian cancer to identify the likely causal variants and genes that mediate associations with cancer risk and survival. He has been awarded both internal and NHMRC grant funding to support these studies. Since 2019, Dylan has held an Honorary Associate Professorship at UQ

As of early 2021, Dylan has authored one conference report, two editorials, two book chapters, six reviews and 31 original research articles. He is first or last author on 20 of these publications and 27 of his publications have been cited at least 10 times. According to CiteScore, since 2010, 53% of his articles have been published in journals ranked in the top 10% and 19% of hispublications are in the 10% most cited publications worldwide.

Dr. Wenyi Gu’s early education was conducted in China which include his undergraduate and master’s degrees in veterinary medicine. In 1996, he migrated to Australia and pursued his PhD study in biochemistry & molecular biology at the Australian National University (ANU). After a short period of work at John Curtin Medical School ANU as a junior scientist, he moved to Brisbane in 2001 for his post-doc at the University of Queensland and currently a post-doctoral research fellow at AIBN. He held a Peter Doherty Fellowship (2006-2009) and was further supported by NHMRC to spend 7 months at Harvard University as a visiting fellow in 2008. Since his post-doctoral research he has been working in the area of using RNAi to treat viral diseases and cancers. He also has a strong background in immunology and vaccine development.

Dr Kevin M. Koo is currently a National Health and Medical Research Council (NHMRC) Investigator Fellow and Prostate Cancer Foundation of Australia (PCFA) Future Leader Fellow at The University of Queensland Centre for Clinical Research (UQCCR). Dr Koo was awarded his PhD (Dean’s Award for Outstanding Thesis) from the Australian Institute for Bioengineering & Nanotechnology (AIBN), UQ in 2018. His PhD research was on the molecular analysis of nucleic acid biomarkers in prostate cancer liquid biopsies (with a particular interest in fusion genes), and the development of associated nanotechnology-based biosensors to facilitate precision cancer treatment.

Post-PhD, he begun a productive postdoctoral career with dual industry/academia appointments: as the Head of Assay Development/Lab Director in XING Technologies Pty Ltd (a Brisbane-based biotech start-up) to undertake product development projects for commercialization of disease in vitro diagnostics, and as an Honorary Fellow/Principal Research Scientist at UQCCR to continue his academic research in precision cancer nanodiagnostics. His research skills and experiences are honed through dedicated career time spent in both academic research and regulated industry environments.

Dr Koo's research encompasses multi-disciplinary fields of molecular biomarker and nanobiosensor development, translation, and commercialization for precision disease management applications. Presently, he is working on the design and development of integrated multi-bioanalyte sensing technologies to resolve the various challenges around holistic disease pathway understanding and clinical biomarker profiling.

Dr Koo's research endeavours have been recognized by a Metrohm Australia-New Zealand Young Chemist Award (2018), Springer Thesis Award (2019) and Queensland Young Tall Poppy Science Award (2023).

Dr Malcolm Lim is an experienced Cancer Biologist and His research interest spans cancer biology, biomarker discovery and theranostic nanomedicine.

He received his PhD from the University of Queensland (UQ) in 2022. His research, conducted in the labs of Professors Sunil Lakhani and Kristofer Thurecht, involved evaluating the efficacy of using nanomedicine for precision delivery of chemo- or radiotherapeutics against biomarkers in brain metastases. For this work, he developed a clinically-relevant brain metastasis mouse model. His research was recognised with the UQ Dean’s Award for Outstanding Thesis 2022. (DOIs: 10.1021/acs.molpharmaceut.3c00558, 10.3791/64216)

Currently, Malcolm serves as a Postdoctoral Research Fellow at the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) and the Thurecht’s Lab at UQ-Centre for Advanced Imaging (CAI) in Australian Institute for Bioengineering and Nanotechnology (AIBN), where he will apply his multidisciplinary expertise to explore radiobiology and radiation-induced biological responses and to advance targeted pharmaceuticals for challenging cancers.

Prior to joining AMTAR, Malcolm served as a Postdoctoral Researcher where he investigated the molecular mechanisms underlying Early Breast Cancers at the Molecular Breast Pathology Lab, UQ-Centre for Clinical Research, under the mentorship of Professors Sunil Lakhani and Peter Simpson. Before his academic career, Malcolm had five years of experience as a histologist, which provided him with a broad skillset in the field.

Dr Malcolm’s research is well-documented in numerous publications in biomedical research journals despite his career stage, reflecting his passion to advancing cancer research.

Over 5 years of experience in translational biomedical research, specialising in monoclonal antibody-based therapies, immuno-oncology, target discovery and theranostics in cancer. My main research focus is on targeted cancer therapies, understanding how target receptor endocytosis affects antibody drug conjugate (ADC) and radioligand therapy delivery, immune-mediated ADCC, and how combination therapies with immune checkpoint inhibitors can potentially improve therapeutic outcomes for patients.

Associate Professor Andy Moore is a Paediatric Oncologist and Director of Research at Children's Health Queensland Hospital & Health Service (CHQ). He is also Director of the Queensland Children's Tumour Bank, a unique resource located on the Queensland Children's Hospital precinct, facilitating local, national and international collaborative research across all childhood cancer types and supporting enrolment of children on clinical trials. A/Prof. Moore's clinical and research interests focus on childhood leukaemia, particularly acute myeloid leukaemia (AML), an aggressive form of leukaemia with a poor prognosis. He also holds a number of leadership and advisory roles, including Deputy Chair of the Australian & New Zealand Childrens Haematology / Oncology Group (ANZCHOG).

I am a Principal Investigator (PI) and a senior research officer (SRO) at Mater research – UQ with excellent clinical and research laboratory skills and expertise in conducting and analyzing laboratory assays and resolving complex research and clinical laboratory problems. I can describe myself as determined, reliable, studious, conscientious, attentive, industrious, diligent, and focused on the timely, quality completion of all lab procedures. I am able to work well under pressure and time constraints within high-volume environments both independently and in collaboration within a team. I am also a highly self-motivated and career-oriented individual with a genuine interest in addressing cancer molecular mechanisms with the goal of developing novel cancer therapeutics and immunotherapy focusing on tumor microenvironment, immunoregulation and signaling pathways in cancer and metastasis.

Dr Abu Sina is currently an NHMRC Emerging Leader Fellow at the Center for Personalized Nanomedicine, Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland, Australia. Prior to this, he served as a Visiting Scientist at the Dana-Farber Cancer Institute, Harvard University, and as a Visiting Research Fellow at the Irving Cancer Research Center, Columbia University, NY, USA.

Dr. Sina has earned both national and international acclaim for his notable contributions to advancing translational-focused nano-diagnostic technologies with a focus on early cancer detection from liquid biopsies. He is one of the few leaders in the world who is driving the liquid biopsy-based multi-cancer early detection (MCED) test program. He has had several media appearances so far which include interviews on national (Channel 9, Channel 7, ABC News, Fox News, etc.) and international Television (CBC News, CTV News Canada, etc.) and Radio (4EB, 4BC, ABC Perth, ABC Sunshine coast, SBS) outlets.

Actively participating in scholarly discussions, Dr. Sina has served as a Keynote Speaker, Invited Speaker, and Session Chair at various national and international conferences and seminars. His commitment to excellence has resulted in several prestigious awards, including the Metrohm-EDRACI Young Electrochemist Award 2021, the Queensland Health and Medical Research Award 2019 from the Queensland State Government of Australia, and recognition as a Fellow of the International Association of Advanced Materials.

Central to his aspirations is a vision to develop point-of-care diagnostic technologies with the potential to revolutionize early disease detection, thereby enhancing overall quality of life.

Dr Haolu Wang currently is a Medical Registrar and Basic Physician Trainee with the Royal Australasian College of Physicians - The Prince Charles Hospital and Redcliffe Hospital (Northside) Rotation. He is also an Honorary Research Fellow in the joint liver cancer research program of Frazer Institute, The University of Queensland and Gallipoli Medical Research Foundation. Dr Wang received his Bachelor of Medicine and Master of Surgery qualifications from Shanghai Jiao Tong University School of Medicine. He was awarded his PhD in Clinical Medicine from The University of Queensland. Dr Wang has worked as a Medical Officer at Renji Hospital, Shanghai Jiao Tong University School of Medicine and as a Researcher Officer at Frazer Institute, The University of Queensland.

Dr Wang has authored over 30 publications of clinical and translational research in liver diseases, including Hepatology, Theranostics, Int J Cancer, J Exp Clin Cancer Res and Pharmacol Ther. His standing in this field is reflected by awards from Australian National Health and Medical Research Council, United European Gastroenterology, European Microscopy Congress, The University of Queensland, Frazer Family Foundation and Shanghai Jiao Tong University.